ELMD
Electromed, Inc.
1
On watch
Electromed's high revenue growth and margins make it compelling amid healthcare sector stability.
The thesis
Electromed develops airway clearance therapy products with 11.6% YoY revenue growth and 7854.0% gross margin. The company's conviction score is 5/100, indicating a WATCHLIST status. Analyst consensus is BUY, with a P/E of 21.6x. High margins and growth make it an interesting setup.
Why now
The current macro context, with geopolitical tensions and market volatility, makes Electromed's stable healthcare sector exposure and strong financials attractive. Revenue growth of 11.6% YoY is a key driver.
What to watch
Next quarter's revenue growth and margin stability will be key indicators of Electromed's continued strong performance. Changes in analyst consensus rating or DCF intrinsic value will also be important to monitor.
Key risks
Valuation risk is present with a P/E of 21.6x, and execution risk could impact high margins and growth. Macro risk from geopolitical tensions, such as those with Iran, could affect market stability.
Theme exposure
Healthcare, Biotech & Devices
DirectElectromed, Inc. operates in medical - devices. That places it inside the Healthcare, Biotech & Devices story.
This brief is generated from our intelligence layers. Treat it as a starting point, not a final word.
Market intelligence only. Not financial advice. Not a recommendation.